EthansCare

A New York attorney, Amanda Reynolds, has filed a federal lawsuit against the IRS, arguing that her golden retriever, Finnegan, should be legally recognized as a dependent for tax purposes. She claims the dog meets all functional requirements of a dependent, but under current tax law, pets are classified as property, not children or dependents.

Her argument:
1. Finnegan relies entirely on her for food, shelter, medical care, training, transportation, and daily supervision.
2. The dog has no independent income, lives exclusively with her, and incurs annual expenses exceeding $5,000.
3. These conditions mirror IRS dependency requirements for human children under Section 152 of the Internal Revenue Code.

In the U.S., pet ownership can cost thousands of dollars each year. Allowing tax deductions for pet expenses could significantly lower taxable income for households with pets. However, pets are legally classified as property rather than dependents. Currently, tax laws permit deductions for animals only in specific situations, such as certified service animals or animals used for business purposes.

This kind of grassroots project highlights how micro‑reviews (restrooms, parking, even waiting times) can shape consumer choices just as much as traditional Yelp or Google reviews. It’s a reminder that small details drive loyalty — a spotless restroom can be as memorable as a great meal. It’s a lighthearted way to build local buzz, but it also creates a shared resource that people can contribute to. Businesses often compete on food, service, or ambiance, but restroom quality is rarely highlighted. A rating page forces accountability in an overlooked area. For travelers, delivery drivers, parents with kids, or anyone on the go, knowing which businesses have clean, accessible restrooms can be genuinely valuable.

Apps like SitOrSquat (originally backed by Charmin) and Flush have tried to map and rate restrooms globally. If the page gains popularity, businesses might actually improve restroom standards to avoid bad ratings — a quirky form of consumer pressure.

Ma*****na is federally classified as a Schedule I drug, alongside he**in and L*D, meaning “no accepted medical use” and “high potential for abuse. Multiple reports (Washington Post, CBS, USA Today) confirm Trump intends to direct federal agencies to reclassify ma*****na to Schedule III. Drugs in this category (e.g., ketamine, Tylenol with codeine, anabolic steroids) are recognized as having medical value and a lower potential for abuse than Schedule I or II substances. Ma*****na would still be federally prohibited, meaning interstate commerce and recreational use remain restricted. Criminal records tied to ma*****na offenses would not be cleared by rescheduling. States that ban ma*****na would remain unaffected.

The Distinction
1. Schedule I (current): Ma*****na is grouped with he**in and L*D, defined as having no accepted medical use and a high potential for abuse.
2. Schedule II (not the plan): Drugs like co***ne, methadone, and oxycodone — still considered highly addictive with limited medical use.
3. Schedule III (the actual plan): Includes ketamine, Tylenol with codeine, and anabolic steroids. These are recognized as having medical value and a lower abuse potential than Schedule I or II.

Implications of Schedule III
1. Medical research: Reclassification would open the door to federally approved cannabis research, which is currently blocked under Schedule I.
2. Tax relief: Cannabis businesses could finally deduct expenses under IRS code 280E, which currently penalizes Schedule I and II drug companies.
3. Banking & finance: While not full legalization, Schedule III could ease access to banking services and reduce compliance risks.
4. Industry impact: Cannabis stocks surged after the announcement, with Tilray, Canopy Growth, and others jumping 20–35%.

Ma*****na would still be federally prohibited—no automatic expungement of criminal records. State laws remain unchanged — states that ban ma*****na would still enforce those bans.